on MAUNA KEA TECHNOLOGIES (EPA:MKEA)
Mauna Kea Technologies Achieves Milestone with CLIMB Study
Mauna Kea Technologies has announced a significant achievement for its Cellvizio technology. The CLIMB study will be featured in the ASGE Presidential Plenary Session at Digestive Disease Week 2026. This session is known for spotlighting impactful endoscopy research.
The CLIMB study, led by Dr. Somashekar Krishna, involved over 500 patients and demonstrated the superior diagnostic capabilities of EUS-nCLE. This method showed higher accuracy in diagnosing pancreatic cystic lesions compared to standard methods.
Cellvizio's selection indicates its growing clinical importance in managing pancreatic cysts. The study also covered real-time diagnosis, artificial intelligence applications, and medico-economic analyses favoring less invasive procedures.
Sacha Loiseau, CEO, emphasized the study's recognition of Cellvizio's accuracy and its potential to influence clinical practices further.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAUNA KEA TECHNOLOGIES news